NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo
Dirk Sibbing/LinkedIn
Nov 23, 2025, 15:15

Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo

Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:

”Positive late-breaking news on a new pathway – Factor XIa inhibition – for antithrombotic treatment for stroke risk reduction

Secondary prevention trial in patients (>12,000 pts) after non-cardioembolic ischemic stroke or high-risk TIA

OCEANIC-STROKE demonstrates superiority of asundexian vs. Placebo (in both study arms in combo with antiplatelet therapy), showing significant reduction in ischemic stroke risk, without increasing bleeding risk

OCEANIC-STROKE is the first successfully completed Phase III study of a Factor XIa inhibitor (50 mg p.o. once daily)

Adding an antithrombotic agent (here: asundexian) to best medical treatment (here: antiplatelet treatment) with significant reduction in ischemic risk and – at the same time – without (!) increasing overall bleeding risk is highly remarkable!

Uncoupling thrombosis- and haemostasis risk”

Read the full article here.

Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo

Stay updated with Hemostasis Today.

asundexian Bleeding Risk Dirk Sibbing Health Hematology Hemostasis Hemostasis Today Medicine OCEANIC-STROKE Placebo stroke thrombosis TIA
NewsFeed